SERUM IRISIN AND LEPTIN LEVELS IN OBESE AND NON-OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME WITH REFERENCE TO GLUCOSE HOMEOSTASIS
DOI:
https://doi.org/10.22159/ijpps.2016v8i10.14160Keywords:
PCOS, Irisin, Leptin, HOMA-IR, NilAbstract
Objective: This study was aimed to evaluate the effect of serum leptin level on irisin level in relation to glucose homeostasis that to be associated with hormonal changes (Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), Prolactin (PRL), Testosterone (TES)) in obese and non-obese women with polycystic ovary syndrome (PCOS). Â
Methods: Fifty women with polycystic ovaries syndrome (PCOS) and thirty-four apparently healthy control women with regular menstruation (28±2days) were included in this study both of PCOS patients and controls were divided into sub-groups according to their body mass index (BMI) into: twenty-five obese (BMI ≥30) with (BMI= 35.934±0.746) and another twenty-five non-obese polycystic ovaries syndrome women (BMI=25.074±0.456). Whereas, controls were divided as seventeen obese (BMI= 37.140±1.470) and seventeen non-obese (BMI= 25.022±0.683) healthy control women with regular menstruation with an age range (20-40 y) and BMI matching that of the patient groups. Venous blood samples were collected to measure serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), LH/FSH, prolactin (PRL), total testosterone (TES), thyroid stimulating hormone (TSH). As well as, fasting glucose, irisin, leptin, and insulin. Besides, estimating Insulin Resistance (HOMA-IR) index, β-cell function was determined using the Homeostasis Model Assessment of β-cell function (HOMA-β).
Results: Serum irisin levels were not significantly different from their corresponding controls, in both obese and non-obese PCOS patients. Whereas, serum irisin levels were elevated significantly in both obese (patients and control) as compared to non-obese (patients and controls), respectively. But, serum leptin levels were significantly elevated in obese PCOS patients as compared to their corresponding control group, non-obese control, and non-obese PCOS patients. However, serum leptin levels were not significantly different in non-obese women groups, both the PCOS and controls. The irisin/insulin ratio expressed no significant variations from its corresponding control in non-obese groups. But the obese PCOS patient's values were highly significantly different as compared to their control (p<0.01). Furthermore, irisin/insulin ratio was elevated significantly in obese control as compared to non-obese patients (p = 0.001), but not with non-obese controls (p=0.114). The leptin/insulin ratio was not significantly varied in PCOS groups from their corresponding control in non-obese (p = 0.094) but in obese PCOS patients, there was significantly different as compared to its control (p = 0.01). Furthermore, leptin to insulin ratio was not significantly different between patients groups (non-obese and obese, p=0.133), nor between the studied controls (p=0.705).
Conclusion: Although serum irisin levels show no significant variation in subjects in relation to PCOS condition, it seems more to be related to BMI, since it's secreted by adipocytes. And because leptin and irisin levels would be elevated in obese subjects that would be related to PCOS pathogenesis. However, irisin/leptin ratio could aid only in the differentiation of patients with PCOS and normal subjects within the same BMI values. Irisin/insulin ratio seems to be a better indicator for PCOS condition regardless to BMI, where it showed significantly lowered values and to be negatively correlated with HOMA-IR in obese and non-obese, and even to be significantly correlated with LH/FSH ratio in obese PCOS patients.
Downloads
References
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis, and diagnosis. Nat Rev Endocrinol 2011;7:219–31.
March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51.
Diamanti Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–11.
MS Bostanci, N Akdemir, B Cinemre, AS Cevrioglu, S Özden, O Ünal. Serum irisin levels in patients with polycystic ovary syndrome. Mehmet Sühha Bostancı 2015;19:4462-8.
Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the amsterdam ESHRE/ASRM-Sponsored 3rd PCOS consensus workshop group. Fertil Steril 2012;97:28–38.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–7.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance, and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012;33:981–1030.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–92.
Shanshan Gao, Yan Cheng, Lingling Zhao, Yuxin Chen, Yu Liu. The relationships of irisin with bone mineral density and body composition in PCOS patients. Diabetes Metab Res Rev 2016;32:421-8.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–35.
Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276–84.
Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236–42.
Leila Amini, Mohammad Reza Sadeghi, Fatemeh Oskuie, Koorosh Kamali, Haleh Maleki. Lipid profile in women with polycystic ovary syndrome. Crescent J Med Biol Sci 2014;1:147-50.
Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental etiology for polycystic ovary syndrome? Hum Reprod Update 2005;11:357–74.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88.
Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946–57.
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535–82.
Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest 1989;83:23–9.
De Sujit Kumar, Sarkar Chandan, Chaudhuri Subhaschandra, Chowdhury Subhankar, Lahiri Tapan Kumar. Serum leptin in a polycystic ovarian syndrome with reference to insulin level. J Obstet Gynecol India 2007;57:339-41.
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457–65.
Park Kh, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung Ke, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013;98:4899-907.
Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014;63:514–25.
Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like develop¬ment of white fat and thermogenesis. Nature 2012;481:463–8.
Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and in-sulin resistance. J Clin Endocrinol Metab 2013;98:E769–78.
Piya MK, Harte AL, Sivakumar K, Tripathi G, Voyias PD, James S, et al. The identification of irisin in human cerebrospinal fluid: in¬fluence of adiposity, metabolic markers, and gestational diabe¬tes. Am J Physiol Endocrinol Metab 2014;306:E512–8.
Aydin S, Kuloglu T, Aydin S. Copeptin, drop in and irisin concen¬trations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides 2013;47:66–70.
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adap¬tive thermogenesis. Cell 1998;92:829–39.
Uldry M, Yang W, St-Pierre J, Lin J, Seale P, Spiegelman BM. The comple¬mentary action of the PGC-1 coactivators in mitochondrial bio¬genesis and brown fat differentiation. Cell Metab 2006;3:333–41.
Villena JA, Carmona MC, Rodriguez de la Concepcion M, Ross-meisl M, Vinas O, Mampel T, et al. Mitochondrial biogenesis in brown adipose tissue is associated with differential expres-sion of regulatory transcription factors. Cell Mol Life Sci 2002;59:1934–44.
Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ, Liang IT. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2014;99:E2539–E2548.
Rotterdam Eshre/Asrm-Sponsored Pcos Consensus Workshop Group. Revised 2003 consensus on diagnostic criterian and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
Wide L, Loraine Ed JA, Bell ET. eds. Human pituitary gonadotropins: hormone assays and their clinical application. 4th ed. London and New York, Churchill Livingstone; 1976. p. 78-140.
L’hermite M Prolactin. Hormonal assays and their clinical application. Edite par Loraine JA, BELL ET. 4th Edition. Churchill Livingstone; 1976. p. 293-332.
Forest MG, Cathiard AM, Bertrand JA. Total and unbound testosterone levels in the newborn and in normal and hypogonadal children: use of a sensitive radioimmunoassay for testosterone. J Clin Endocrinol Metab 1973;36:1132–42.
Tunbridge WMG, Hall R. Thyrohf-stimulating hormone. In: Hormone Assays and Their Clinical Application. 2nd ed. JA Loraine, ET Bell. Eds. Churchill Livingstone, London, UK; 1976. p. 175-92.
Barham D, Trindoer P. An improved colour reagent for the determination of blood glucose by the oxidative system. Analyst 1972;97:142-5.
Portsmann T, Kiessig ST. Enzyme immunoassay techniques, an overview. J Immunol Methods 1992;150:21.
Avrameas S. Amplification systems in Immun enzymatic techniques. J Immunol Methods 1992;150:23-32.
MK Sinha, I Opentanova, JP Ohannesian, JW Kolaczynski, ML Heiman, J Hale, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 1996;98:1277-82.
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.
Starr JIl, Mako ME, Juhn D. Measurement of serum proinsulin-like material: cross-reactivity of porcine and human proinsulin in the insulin radioimmunoassay. J Lab Clin Med 1978;91:691-2.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
Ioanna Gouni-Berthold, Heiner K Berthold, Joo Young Huh, Reena Berman, Nadine Spenrath, Wilhelm Krone, et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells Ex vivo. PLoS One 2013;8:e72858.
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61:1725–38.
Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365–9.
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 2013;39:125–30.
Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, MartÃnez JA, et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and the following weight regain in obese men and women: irisin and human adiposity. Am J Hum Biol 2014;26:198–207.
Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013;100:96–101.
Aydin S, Aydin S, Kuloglu T, Yilmaz M, Kalayci M, Sahin I, et al. Alterations of irisin concentrations in saliva and serum of obese and normal weight subjects, before and after 45 min of a Turkish bath or running. Peptides 2013;50:13–8.
Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014;63:207–17.
Timea Kurdiova, Miroslav Balaz, Marek Vician, Denisa Maderova, Miroslav Vlcek, Ladislav Valkovic, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies: human Fndc5/irisin in prediabetes, type 2 diabetes and exercise. J Physiol 2014;592:1091–107.
Timmons Ja, Baar K, Davidsen Pk, Atherton PJ. Is iris in a human exercise gene? Nature 2012;488:E9-E10.
Kuzmicki M, Telejko B, Lipinska D, Pliszka J, Szamatowicz M, Wilk J, et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol 2014;30:636-9.
Yuksel MA, Oncul M, Tuten A, Imamoglu M, Acikgoz AS, Kucur M, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract 2014;104:171–5.
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012;61:1725–38.
Catalan V, Gomez-Ambrosi J, Rodriguez A, Salvador J, Frühbeck G. Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 2009;10:239-54.
Boström P, Wu J, Jedrychowski Mp, Korde A, Ye L, Lo Jc, et al. A PGC1-alphadependent myokine that drives the brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-8.
Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrøm V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006;155:337-45.
Juha Rouru, Leena Anttila, Pertti Koskinen, Tuula-Anneli Penttila, Kerttu Irjala, Risto Huupponen, et al. Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:1697-700.
Published
How to Cite
Issue
Section
